Clinical Trials | June 14, 2026
Breakthrough approval in prostate cancer for AstraZeneca therapy
The decision was driven by results from the Phase III CAPItello-281 trial,
The decision was driven by results from the Phase III CAPItello-281 trial,
Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
The filing is backed by results from the pivotal SERENA-6 Phase III trial
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
